Zobrazeno 61 - 70
of 560
pro vyhledávání: ''
Autor:
Thomas V. Jones, Lara Fallon
Publikováno v:
Annals of the rheumatic diseases.
We read with interest the recently published European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis (PsA) with pharmacological therapies1 and the associated systematic literature research (SLR)2; we welco
Publikováno v:
Annals of the Rheumatic Diseases
We thank Santos-Moreno et al for their response to our commentary.1 2 The authors provide data on cardiovascular adverse events associated with maintenance antimalarial use for patients with rheumatoid arthritis (RA). In addition to our previous corr
Publikováno v:
Annals of the Rheumatic Diseases
We read the letter by Mathian et al with great interest.1 In their paper, the authors report on the course of COVID-19 in 17 patients with systemic lupus erythematosus (SLE). The data suggest that patients with SLE on hydroxychloroquine (HCQ) are not
Autor:
Ann-Sophie De Craemer, Philippe Carron, Mikkel Østergaard, Dirk Elewaut, Lennart Jans, Liselotte Deroo, Manouk de Hooge, Simon Krabbe, Min Chen, Thomas Renson, Filip Van den Bosch
Publikováno v:
Annals of the rheumatic diseases. 80(1)
ObjectivesTo assess axial involvement on MRI in early peripheral spondyloarthritis (pSpA) and to evaluate whether axial inflammation predicts relapse on treatment withdrawal.MethodsFifty-six patients with early, active, newly diagnosed pSpA underwent
Publikováno v:
Annals of the Rheumatic Diseases
We thank Gyorfi et al for their correspondence.1 The case they present demonstrates a potentially important point that was reported in our manuscript2: the effect of systemic glucocorticoids may worsen outcomes in patients with rheumatic disease. How
Autor:
Sara Monti, Carlomaurizio Montecucco
Publikováno v:
Annals of the Rheumatic Diseases
We appreciated the comment from Schulze-Koops et al 1 in response to our paper on the clinical course and outcome of COVID-19 in a cohort of patients treated with biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).2
Autor:
Laurence Seidel, Marjorie Gangolf, Zoé Gendebien, Clio Ribbens, Béatrice Andre, Christian Von Frenckell, Marie Thys, Michel Malaise, Olivier Malaise
Publikováno v:
Annals of the Rheumatic Diseases
We read with interest the article of Bozzalla Cassione et al about COVID-19 incidence in their systemic lupus erythematosus (SLE) cohort.1 Their study adds useful epidemiological information about COVID-19 risk in SLE.1 They suggest that hydroxycholo
Autor:
Zahir Amoura, Alexis Mathian
Publikováno v:
Annals of the Rheumatic Diseases
We thank Plus et al for their interest in our study reporting on the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) in a case series of patients with systemic lupus erythematosus (SLE) under long-term t
Autor:
Roberto Caporali, Martina Biggioggero, Ennio Giulio Favalli, Nicoletta Del Papa, Orazio De Lucia
Publikováno v:
Annals of the Rheumatic Diseases
The potential role of chloroquine (CQ) and hydroxychloroquine (HCQ) in the management of COVID-19 is certainly of relevance in this health emergency scenario. For this reason, we read with great interest the letter published by Romao and colleagues h
Publikováno v:
Annals of the Rheumatic Diseases
We read with great interest the article by D’Silva et al concerning clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease.1 In this study, the authors mentioned that patients with and without rheumatic disease had si